TR200103099T2 - Fosfodiesteraz IVinhibitörü 1-amino triazoloc 4,3-a!kinazolin-5-on ve/veya-5-tionlar - Google Patents

Fosfodiesteraz IVinhibitörü 1-amino triazoloc 4,3-a!kinazolin-5-on ve/veya-5-tionlar

Info

Publication number
TR200103099T2
TR200103099T2 TR2001/03099T TR200103099T TR200103099T2 TR 200103099 T2 TR200103099 T2 TR 200103099T2 TR 2001/03099 T TR2001/03099 T TR 2001/03099T TR 200103099 T TR200103099 T TR 200103099T TR 200103099 T2 TR200103099 T2 TR 200103099T2
Authority
TR
Turkey
Prior art keywords
thions
quinazolin
phosphodiesterase
triazoloc
inhibitor
Prior art date
Application number
TR2001/03099T
Other languages
English (en)
Inventor
Gaudilliere Bernard
Lavalette R�M�
Andrianjara Charles
Breuzard Francine
Original Assignee
Warner Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Company filed Critical Warner Lambert Company
Publication of TR200103099T2 publication Critical patent/TR200103099T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Bu bulus, R grubunun nitrojen 3 ya da 4 üzerindeki pozisyon izomerleri olan formül (I) ve (II)'nin trizolo[4,3-a] kinazolin-5-on ve/veya 5-tiyonlari ile ilgilidir.Istege bagli olarak, bu bulus bunlarin rasemik biçimleri, izomerleri ve farmasötik olarak kabul edilebilir tuzlari ile de ilgilidir. Bulus ayrica bunun bir üretim metodu ve adi geçen türevleri içeren bilesimlerle de ilgilidir. Bilesikler a fosfodiesteraz IV (PDE-4) inibitörleri olarak islev görürler.
TR2001/03099T 1999-04-28 2000-04-28 Fosfodiesteraz IVinhibitörü 1-amino triazoloc 4,3-a!kinazolin-5-on ve/veya-5-tionlar TR200103099T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9905398A FR2792938B1 (fr) 1999-04-28 1999-04-28 NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV

Publications (1)

Publication Number Publication Date
TR200103099T2 true TR200103099T2 (tr) 2002-12-23

Family

ID=9544983

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03099T TR200103099T2 (tr) 1999-04-28 2000-04-28 Fosfodiesteraz IVinhibitörü 1-amino triazoloc 4,3-a!kinazolin-5-on ve/veya-5-tionlar

Country Status (34)

Country Link
US (1) US6828315B1 (tr)
EP (1) EP1177195B1 (tr)
JP (1) JP2002543199A (tr)
KR (1) KR20020008166A (tr)
CN (1) CN1352644A (tr)
AP (1) AP2001002309A0 (tr)
AT (1) ATE234840T1 (tr)
AU (1) AU4411500A (tr)
BG (1) BG106026A (tr)
BR (1) BR0010072A (tr)
CA (1) CA2388658A1 (tr)
DE (1) DE60001735T2 (tr)
DK (1) DK1177195T3 (tr)
DZ (1) DZ3154A1 (tr)
EA (1) EA004373B1 (tr)
EE (1) EE200100566A (tr)
ES (1) ES2194779T3 (tr)
FR (1) FR2792938B1 (tr)
HK (1) HK1044938B (tr)
HR (1) HRP20010794B1 (tr)
HU (1) HUP0202656A3 (tr)
IL (1) IL146178A0 (tr)
IS (1) IS6114A (tr)
MA (1) MA27343A1 (tr)
MX (1) MXPA01010888A (tr)
NO (1) NO20015235L (tr)
OA (1) OA11875A (tr)
PL (1) PL351951A1 (tr)
PT (1) PT1177195E (tr)
SK (1) SK15322001A3 (tr)
TR (1) TR200103099T2 (tr)
WO (1) WO2000066584A1 (tr)
YU (1) YU76401A (tr)
ZA (1) ZA200108847B (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
PA8539501A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
KR20040007596A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
EP1285922A1 (en) * 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
FR2832711B1 (fr) * 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
JP4700965B2 (ja) * 2002-11-06 2011-06-15 あすか製薬株式会社 ピラゾロナフチリジン誘導体
PL378245A1 (pl) * 2003-01-09 2006-03-20 Astellas Pharma Inc. Pochodne pirolopirydazyny
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010505811A (ja) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103224498B (zh) * 2013-05-07 2015-10-28 陈定奔 两种唑并喹唑啉酮稠杂环的新合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865824A (en) * 1972-03-07 1975-02-11 Icn Pharmaceuticals 2-Aryl-7-substituted pyrazolo {8 1,5{i a{b {9 1,3,5-triazines
US3850932A (en) * 1973-06-28 1974-11-26 Sandoz Ag 5-(2-carboxy and 2-carboalkoxy-phenylamino)-1,2,4-triazolo-quinazolines
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
CA2223624C (en) * 1995-06-06 2001-02-20 Pfizer Inc. Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.

Also Published As

Publication number Publication date
IS6114A (is) 2001-10-19
HUP0202656A2 (hu) 2002-12-28
HRP20010794B1 (en) 2004-06-30
HUP0202656A3 (en) 2004-12-28
EP1177195A1 (fr) 2002-02-06
ZA200108847B (en) 2002-11-27
EA200100994A1 (ru) 2002-06-27
OA11875A (en) 2006-03-29
WO2000066584A1 (fr) 2000-11-09
PL351951A1 (en) 2003-07-14
HK1044938B (zh) 2003-12-24
FR2792938B1 (fr) 2001-07-06
HK1044938A1 (en) 2002-11-08
DZ3154A1 (fr) 2000-11-09
BG106026A (bg) 2002-05-31
CA2388658A1 (en) 2000-11-09
IL146178A0 (en) 2002-07-25
MXPA01010888A (es) 2003-06-24
MA27343A1 (fr) 2005-06-01
DE60001735T2 (de) 2004-02-05
EE200100566A (et) 2003-02-17
YU76401A (sh) 2004-07-15
US6828315B1 (en) 2004-12-07
EA004373B1 (ru) 2004-04-29
EP1177195B1 (fr) 2003-03-19
PT1177195E (pt) 2003-07-31
BR0010072A (pt) 2002-02-05
SK15322001A3 (sk) 2002-11-06
CN1352644A (zh) 2002-06-05
ES2194779T3 (es) 2003-12-01
DK1177195T3 (da) 2003-07-14
DE60001735D1 (de) 2003-04-24
FR2792938A1 (fr) 2000-11-03
AU4411500A (en) 2000-11-17
KR20020008166A (ko) 2002-01-29
JP2002543199A (ja) 2002-12-17
NO20015235D0 (no) 2001-10-26
HRP20010794A2 (en) 2003-04-30
AP2001002309A0 (en) 2001-12-31
NO20015235L (no) 2001-12-21
WO2000066584B1 (fr) 2001-02-15
ATE234840T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
TR200103099T2 (tr) Fosfodiesteraz IVinhibitörü 1-amino triazoloc 4,3-a!kinazolin-5-on ve/veya-5-tionlar
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
TR200100472T2 (tr) Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
DK1277754T3 (da) Imidazopyridinderivater
TR199903148T2 (tr) Antimetastatik ve antitümör etkinligi olan barbitürik asit türevleri.
ATE292634T1 (de) Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
DK1001930T3 (da) N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
BR9811099A (pt) Inibidores de urocinase
PT1037886E (pt) Inibidores de angiogenese de triazina
AP2001002205A0 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase.
TR199900486T2 (tr) Aziniloksi ve fenoksi-diaril-karbonasit türevleri.
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
TR200001452T2 (tr) Bifenilamidin türevleri.
TR200002099A2 (tr) Siklobüten türevleri, bunların hazırlanması ve terapötik kullanımları
NO20000957L (no) Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer
DE60031886D1 (de) Purinderivate
DE69709933D1 (en) Aromatische amidinderivate als selektive thrombininhibitoren
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
DK0870763T3 (da) Kondenserede piperidinderivater som inhibitorer for syntese af nitrogenmonoxid
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
DK0861250T3 (da) Amindin- og isothiourinstofderivater som inhibitorer for nitrogenmonoxidsyntase